Clinical trials: Critical Ill Patients
- Condition Critical Ill Patients
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Critical Illness, Hyperglycemia
Effects of a Complete Diet in Critically Ill Patients With Stress Hyperglycemia
The aim of the study is to evaluate the beneficial effects of the administration of a complete diet rich in monounsaturated fatty acids (MUFA) and slow absorption carbohydrate in patients with stress hyperglycemia(T-Diet Plus…
- Conditions
- Critical Illness, Hyperglycemia, Dietary Modification, Metabolic Stress Hyperglycemia
- Trial name
- NCT01233726
- Testing
- T-Diet plus Diabet IR, ISOSOURCE PROTEIN FIBRE, GLUCERNA SELECT
- Where
- 2 sites in Spain
- Volunteers
- 159 people
- Sponsor
- Vegenat, S.A.
Critically Ill
Hypocaloric Nutrition in Critically Ill Patients
The aim of this study is to compare two nutritional regimes in critically ill patients. Patients will be randomized to standard care (25 kcal per kg) or to hypocaloric nutrition (15 kcal per kg).
- Trial name
- RuRaL (NCT01531335)
- Testing
- Hypocaloric hyperproteic nutrition, Standard care
- Where
- Colombia
- Volunteers
- 80 people
- Sponsor
- Lafrancol S.A.
Anemia
Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa
The purpose of this trial is to evaluate the physical function outcomes in anemic, critically ill, trauma subjects treated with epoetin alfa (PROCRIT®) compared to placebo.
- Trial name
- NCT00210626
- Testing
- PROCRIT
- Where
- 21 sites in United States
- Volunteers
- 192 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Critically Ill, Pneumonia
Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007)
The purpose of this study is to evaluate the pharmacokinetics and lung penetration of intravenous Ceftolozane/tazobactam in critically ill participants.
- Trial name
- NCT02387372
- Testing
- Ceftolozane/Tazobactam - Multiple Doses, Ceftolozane/Tazobactam - Single Dose
- Volunteers
- 37 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Critical Illness, Enteral Nutrition
TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)
The purpose of this study is to assess the treatment effect of intravenous TAK-954 in improving the average daily protein adequacy received through enteral nutrition in critically-ill participants developing EFI.
- Conditions
- Critical Illness, Enteral Nutrition, Enteral Feeding Intolerance
- Trial name
- NCT03477903
- Testing
- TAK-954, Metoclopramide, Normal Saline
- Where
- 44 sites in United States, Australia and 2 more
- Volunteers
- 1 people
- Sponsor
- Millennium Pharmaceuticals, Inc.